| PROQR THERAPEUTICS EO-,04 |
| Niederlande |
| Gesundheit |
| NL0010872495 / A12B97 |
| 0PQ (Frankfurt) / PRQR (NASDAQ) |
| FRA:0PQ, ETR:0PQ, 0PQ:GR, NASDAQ:PRQR |
| - |
| https://www.proqr.com/ |
|
ProQR Therapeutics N.V. is a biotechnology company specializing in the development of transformative RNA-based therapies for genetic disorders. Founded in 2012 and based in the Netherlands, the company focuses on targeting genetic eye diseases like L..
>Volltext.. |
| 174.03 Mio. EUR |
| 106.55 Mio. EUR |
| 13.64 Mio. EUR |
| -44.57 Mio. EUR |
| -46.31 Mio. EUR |
| -0.44 EUR |
| 13.86 Mio. EUR |
| 82.09 Mio. EUR |
| -50.83 Mio. EUR |
| 2.31 |
| -28.58% |
| -52.61% |
| - |
| - |
| - |
| - |
| PROQR |
| 25.06.26 |
|